Tim Cunniff, Vice President of Global Regulatory Affairs at Lundbeck, presented at last year's World Orphan Drug Congress USA on the topic â€˜Incorporating orphan indications into a CNS business model.'
Do you want to learn more about:
- Lundbeck’s experience in the orphan drugs space
- Key considerations in combining orphan indications into a broader CNS strategy
- Overcoming challenges from clinical development through commercialization
If so, you need to check out the video below: